FAIR VALUE MEASUREMENTS - Additional Information (Details) € in Millions, $ in Millions	3 Months Ended		12 Months Ended
	Dec. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 04, 2021 EUR (€)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate amortization expense related to finite-lived intangible assets			$ 2,300	$ 1,800	$ 1,700
In-process research and development impairments			50	2,700	$ 0
Manufacturing Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Write-off			$ 381
In Process Research And Development Bulveritide
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
In-process research and development impairments	$ 50
Fair Value, Nonrecurring | Galapagos
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate amortization expense related to finite-lived intangible assets	51
Fair Value, Nonrecurring | In Process Research And Development Trodelvy For HR+/HER2-
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
In-process research and development impairments		$ 2,700		$ 2,700
Fair Value, Nonrecurring | In Process Research And Development Bulveritide
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
In-process research and development impairments	$ 50
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency derivative contract maturities (in months)	18 months		18 months
Maximum | MYR
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liability for MYR GmbH (“MYR”) contingent consideration | €						€ 300